|
業務類別
|
-- |
|
業務概覽
|
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from PRC. |
| 公司地址
| Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203 |
| 電話號碼
| +86 2138101800 |
| 傳真號碼
| +86 2138101808 |
| 公司網頁
| https://www.huamedicine.com |
| 員工數量
| 168 |
| Dr. Li Chen |
Chief Executive Officer and Director |
-- |
26/04/2023 |
| Mr. Chien Cheng George Lin |
Director, Executive Vice President and Chief Strategy Officer |
-- |
26/04/2023 |
|
|
| Mr. Robert Taylor Nelsen |
Chairman of the Board |
26/04/2023 |
| Mr. William Robert Keller |
Independent Director |
26/04/2023 |
| Mr. Yiu Leung Cheung |
Independent Director |
26/04/2023 |
| Mr. Yiu Wa Alec Tsui |
Independent Director |
26/04/2023 |
| Ms. Zhao Wei |
Director |
26/04/2023 |
| Dr. Li Chen |
Chief Executive Officer and Director |
26/04/2023 |
| Mr. Chien Cheng George Lin |
Director, Executive Vice President and Chief Strategy Officer |
26/04/2023 |
|
|
|
|
